Table 5.
Impact of IBD clinical activity and exposure to IBD drugs at clinical onset of SVI in cases on the risk of SVI.
| Cases of SVI (n = 31) | Controls (n = 124) | Univariate analysis |
Multivariate analysis |
|||||
|---|---|---|---|---|---|---|---|---|
| n (%) | n (%) | Odds ratio | 95% CI | p value | Odds ratio | 95% CI | p value | |
| Clinically active disease | 13 (41.9) | 23 (18.6) | 3.86 | 1.46–10.17 | 0.006 | 3.35 | 1.23-9.23 | 0.02 |
| 5-ASA | 10 (32.3) | 53 (42.7) | 0.62 | 0.26–1.46 | 0.27 | – | – | – |
| Corticosteroids | 3 (9.7) | 12 (9.7) | 1.00 | 0.25–4.00 | 1 | – | – | – |
| Methotrexate | 4 (12.9) | 11 (8.9) | 1.53 | 0.44–5.21 | 0.50 | |||
| Azathioprine or 6-mercaptopurine | 20 (64.5) | 42 (33.9) | 3.94 | 1.55–10.02 | 0.004 | 3.48 | 1.36–8.90 | 0.009 |
| Anti-TNF agent | 6 (19.4) | 21 (16.9) | 1.18 | 0.43–3.25 | 0.75 | – | – | – |
| Combination therapya | 4 (12.9) | 11 (8.9) | 1.47 | 0.45–4.75 | 0.51 | – | – | – |
IBD: inflammatory bowel disease; SVI: serious viral infection; CI: confidence interval.
a
Anti-TNF agent and azathioprine, 6-mercaptopurine or methotrexate.